PT  - JOURNAL ARTICLE
AU  - Xiaodong Luan
AU  - Weijuan Shang
AU  - Yifei Wang
AU  - Wanchao Yin
AU  - Yi Jiang
AU  - Siqin Feng
AU  - Yiyang Wang
AU  - Meixi Liu
AU  - Ruilin Zhou
AU  - Zhiyu Zhang
AU  - Feng Wang
AU  - Wang Cheng
AU  - Minqi Gao
AU  - Hui Wang
AU  - Wei Wu
AU  - Ran Tian
AU  - Zhuang Tian
AU  - Ye Jin
AU  - Hualiang Jiang
AU  - Leike Zhang
AU  - H. Eric Xu
AU  - Shuyang Zhang
TI  - Structure Basis for Inhibition of SARS-CoV-2 by the Feline Drug GC376
AID  - 10.1101/2020.06.07.138677
DP  - 2020 Jan 01
TA  - bioRxiv
PG  - 2020.06.07.138677
4099  - http://biorxiv.org/content/early/2020/06/08/2020.06.07.138677.short
4100  - http://biorxiv.org/content/early/2020/06/08/2020.06.07.138677.full
AB  - The pandemic of SARS-CoV-2 coronavirus disease-2019 (COVID-19) caused by SARS-COV-2 continues to ravage many countries in the world. Mpro is an indispensable protein for viral translation in SARS-CoV-2 and a potential target in high-specificity anti-SARS-CoV-2 drug screening. In this study, to explore potential drugs for treating COVID-19, we elucidated the structure of SARS-CoV-2 Mpro and explored the interaction between Mpro and GC376, an antiviral drug used to treat a range of coronaviruses in Feline via inhibiting Mpro. The availability and safety of GC376 were proved by biochemical and cell experiments in vitro. We determined the structure of an important protein, Mpro, in SARS-CoV-2, and revealed the interaction of GC376 with the viral substrate and inhibition of the catalytic site of SARS-CoV-2 Mpro.Competing Interest StatementThe authors have declared no competing interest.